Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145/LN-145-S1) for the Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT03083873 is registered in ClinicalTrials.gov with Iovance Biotherapeutics, Inc. as lead sponsor.

NCT NCT03083873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03083873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145/LN-145-S1) for the Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Iovance Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 9, 2017
Completion date
August 8, 2022
Enrollment
64 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck